Achieving orphan designation for placental insufficiency: annual incidence estimations in Europe

Abstract

Objective To determine whether a novel therapy for placental insufficiency could achieve orphan drug status by estimating the annual incidence of placental insufficiency, defined as an estimated fetal weight below the 10th centile in the presence of abnormal umbilical artery Doppler velocimetry, per 10 000 European Union (EU) population as part of an application for European Medicines Agency (EMA) orphan designation. Design Incidence estimation based on literature review and published national and EU statistics. Setting and population European Union. Methods Data were drawn from published literature, including national and international guidelines, international consensus statements, cohort studies and randomised controlled trials, and published national and EU statistics, including birth rates and stillbirth rates. Rare disease databases were also searched. Results The proportion of affected pregnancies was estimated as 3.17% (95% CI 2.93–3.43%), using a weighted average of the results from two cohort studies. Using birth rates from 2012 and adjusting for a pregnancy loss rate of 1/100 gave an estimated annual incidence of 3.33 per 10 000 EU population (95% CI 3.07–3.60 per 10 000 EU population). This fell below the EMA threshold of 5 per 10 000 EU population. Conclusions Maternal vascular endothelial growth factor gene therapy for placental insufficiency was granted EMA orphan status in 2015 after we demonstrated that it is a rare, life‐threatening or chronically debilitating and currently untreatable disease. Developers of other potential obstetric therapies should consider applying for orphan designation, which provides financial and regulatory benefits. Tweetable abstract Placental insufficiency meets the European Medicines Agency requirements for orphan disease designation.

Maternal Sildenafil vs Placebo in Pregnant Women With Severe Early-Onset Fetal Growth Restriction

“…Severe early onset fetal growth restriction is a rare condition, complicating approximately 0.4% of all pregnancies. 1,2 It is associated with a high risk of fetal death, iatrogenic preterm birth, long-lasting stay at the neonatal intensive care unit, neonatal mortality, and long-term morbidity. 3,4 Severe earlyonset fetal growth restriction is also strongly associated with neurodevelopmental impairment later in childhood.…”

An Ensemble Methods for Medical Insurance Costs Prediction Task

“…The governments pledged hundreds of millions of dollars to support the local digital health industry. The prediction of individual health insurance costs is an essential task in the healthcare system, particularly for people with orphan diseases [2][3][4]: prevention and medical insurance help to decrease the cost of treatment.…”

Comparison of Efficiency and Function of Vascular Endothelial Growth Factor Adenovirus Vectors in Endothelial Cells for Gene Therapy of Placental Insufficiency

“…10 The European Medicines Agency Committee for Orphan Medicinal Products (EMA COMP) granted orphan status in 2015, with an estimated annual incidence of 3.33 per 10,000 EU population (95% confidence interval 3.07-3.60). 11,12 Normal vasculogenesis, the formation of new blood vessels, and angiogenesis or blood vessel growth are vital for functional development of the placenta and healthy pregnancy outcome. Members of the vascular endothelial growth factor (VEGF) family and their receptors are key regulators in trophoblast invasion and in angiogenesis of the placenta and maternal decidua.…”